Pheno- and Genotyping the Prescription of Drugs Metabolized by CYP2D6

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Bulletin of experimental biology and medicine

• Publication date

  2002-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1023/A:1021188315536PMID 12459840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytochrome P450 Substrate Specificities, Substrate Structural Templates and Enzyme Active Site Geometries

  1999cited by this paper
• Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.

  1997cited by this paper
• Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.

  1994cited by this paper
• Debrisoquine metabolism and genetic predisposition to lung cancer.

  1989cited by this paper

• Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA)

  2018cites this paper
• Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI)

  2008cites this paper